Amgen Inc. (NASDAQ:AMGN) is a leading biotechnology company known for its innovative therapies and treatments. The company focuses on developing medicines for serious illnesses, including cancer and cardiovascular diseases. Amgen competes with other biotech giants like Biogen and Gilead Sciences. On December 3, 2025, David Taylor engaged in a sale transaction involving Amgen shares valued between $1,001 and $15,000.
Cerity Partners LLC has shown confidence in Amgen by increasing its holdings by 4.2% during the second quarter. The firm now owns 423,019 shares, having added 16,972 shares, with a total investment valued at approximately $118 million. This represents about 0.08% of Amgen's total market value, highlighting the firm's strategic interest in the company.
Other institutional investors have also adjusted their positions in Amgen. Brighton Jones LLC increased its holdings by 23.5%, now owning 27,468 shares valued at $7.2 million. Similarly, Chicago Partners Investment Group LLC raised its stake by 21.1% during the first quarter, indicating a broader trend of institutional interest in Amgen.
Amgen's current stock price is $324.72, reflecting a decrease of approximately 1.57%, with a drop of $5.18 today. The stock has fluctuated between a low of $322.02 and a high of $329.67 during the trading day. Over the past year, Amgen's stock has reached a high of $346.38 and a low of $253.30, showing significant volatility.
Amgen's market capitalization is approximately $174.85 billion, indicating its substantial presence in the biotechnology sector. The trading volume for the day is 961,888 shares, reflecting active investor interest. Despite recent fluctuations, Amgen remains a key player in the biotech industry, with strong institutional backing.
